ArticlePeerJ2026
Prognostic model of patients with acute pancreatitis based on prothrombin time-international normalized ratio to albumin ratio: a single-center retrospective study.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prothrombin time-international normalized ratio to albumin ratio (PTAR) serves as a prognostic biomarker in several diseases, yet its role in predicting the mortality of acute pancreatitis (AP) remains unclear. This study aimed to investigate the association between PTAR and the 30-day outcomes in AP patients. Methods: We retrospectively analysed data from 965 patients hospitalized with AP between January 2017 and December 2019, collecting baseline clinical characteristics and laboratory data. Using logistic regression analysis and the least absolute shrinkage and selection operator regression, we developed a prognostic nomogram based on PTAR. The nomogram's predictive performance and calibration were assessed Results: Among the 965 patients, 43 (4.5%) died within 30 days. Multivariate analysis identified seven risk factors independently associated with 30-day mortality of patients with AP: Age, neutrophil percentage, platelets, fibrinogen, aspartate aminotransferase, blood urea nitrogen, and PTAR. The model incorporating these factors, including PTAR, demonstrated excellent discrimination and calibration ability in assessing 30-day mortality (area under the curve (AUC) = 0.914, 95% confidence interval (CI) [0.877-0.951]). Kaplan-Meier survival curve analysis showed that AP patients with a nomogram value >0.082 had a significantly higher risk of 30-day mortality ( Conclusions: PTAR holds clinical value in evaluating the 30-day prognosis of AP patients. The PTAR-based model could be useful independently or as a complement to conventional measures to support clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.